{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:46:08Z","timestamp":1794901568885,"version":"4.9.1"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.pharmthera.2025.108861","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:58:08Z","timestamp":1744725488000},"page":"108861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure"],"prefix":"10.1016","volume":"270","author":[{"given":"Matteo","family":"Armillotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Paolisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Di Dalmazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Amicone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Canton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Suma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Fo\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Pizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmthera.2025.108861_bb0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The Association of Sodium-Glucose Cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with Cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC. CardioOncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108861_bb0010","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0015","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1038\/s41467-020-18160-x","article-title":"Intracellular sodium elevation reprograms cardiac metabolism","volume":"11","author":"Aksentijevi\u0107","year":"2020","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108861_bb0020","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1016\/j.clinthera.2020.09.008","article-title":"Potential therapeutic effects of sodium glucose-linked cotransporter 2 inhibitors in stroke","volume":"42","author":"Al Hamed","year":"2020","journal-title":"Clinical Therapeutics"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108861_bb0025","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of sodium-glucose Cotransporter-2 inhibitors on endothelial function: A systematic review of preclinical studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2025.108861_bb0035","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0040","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","article-title":"Empagliflozin limits myocardial infarction in vivo and cell death in vitro: Role of STAT3, mitochondria, and redox aspects","volume":"8","author":"Andreadou","year":"2017","journal-title":"Frontiers in Physiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108861_bb0045","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaccao.2024.09.006","article-title":"Multimodality imaging in the diagnostic work-up of patients with cardiac masses: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Angeli","year":"2024","journal-title":"JACC. CardioOncology"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108861_bb0050","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a Preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-642-41588-3_7","article-title":"The role of late I Na in development of cardiac arrhythmias","volume":"221","author":"Antzelevitch","year":"2014","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2017.08.013","article-title":"Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action","volume":"277","author":"Arafa","year":"2017","journal-title":"Chemico-Biological Interactions"},{"issue":"37","key":"10.1016\/j.pharmthera.2025.108861_bb0065","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"European Heart Journal"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108861_bb0070","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.3390\/cells11213372","article-title":"Empagliflozin induced ketosis, upregulated IGF-1\/insulin receptors and the canonical insulin signaling pathway in neurons, and decreased the excitatory neurotransmitter glutamate in the brain of non-diabetics","volume":"11","author":"Avgerinos","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 inhibitor use and risk of clinical events in patients with Cancer therapy-related cardiac dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC. Heart Failure"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108861_bb0080","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108861_bb0085","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109569","article-title":"Brain-derived neurotrophic factor alleviates diabetes mellitus-accelerated atherosclerosis by promoting M2 polarization of macrophages through repressing the STAT3 pathway","volume":"70","author":"Bi","year":"2020","journal-title":"Cellular Signalling"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/L20-0549","article-title":"Rosuvastatin myotoxicity after starting Canagliflozin treatment: A case report","volume":"173","author":"Brailovski","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-018-0943-5","article-title":"SGLT2 inhibitors and mechanisms of hypertension","volume":"20","author":"Briasoulis","year":"2018","journal-title":"Current Cardiology Reports"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108861_bb0105","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/echo.15854","article-title":"Clinical impact of multimodality assessment of myocardial viability","volume":"41","author":"Canton","year":"2024","journal-title":"Echocardiography (Mount Kisco, N.Y.)"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0115","doi-asserted-by":"crossref","first-page":"1012220","DOI":"10.3389\/fcvm.2022.1012220","article-title":"In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study","volume":"9","author":"Cesaro","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0120","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014A novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108861_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0130","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3390\/jcm12072695","article-title":"SGLT2 inhibitors: Statins or ACE-inhibitors of the 21st century?","volume":"12","author":"Correale","year":"2023","journal-title":"Journal of Clinical Medicine"},{"issue":"36","key":"10.1016\/j.pharmthera.2025.108861_bb0135","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108861_bb0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The Cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC. CardioOncology"},{"issue":"23","key":"10.1016\/j.pharmthera.2025.108861_bb0145","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 inhibitors in Cancer treatment-mechanisms of action and emerging new perspectives","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12883-018-1086-4","article-title":"Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy","volume":"18","author":"Erdogan","year":"2018","journal-title":"BMC Neurology"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.100847","article-title":"Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: A comparative effectiveness study on propensity score matched cohorts at low renal risk","volume":"38","author":"Fadini","year":"2024","journal-title":"The Lancet Regional Health. Europe"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0165","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108861_bb0170","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s disease: Targeting the cholinergic system","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Current Neuropharmacology"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108861_bb0180","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0185","doi-asserted-by":"crossref","first-page":"1011429","DOI":"10.3389\/fcvm.2022.1011429","article-title":"Benefits of SGLT2 inhibitors in arrhythmias","volume":"9","author":"Gao","year":"2022","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108861_bb0190","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","article-title":"Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: An updated systematic review and meta-analysis of randomised cardiovascular outcome trials","volume":"8","author":"Ghosh-Swaby","year":"2020","journal-title":"The Lancet. Diabetes & Endocrinology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108861_bb0195","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-Transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC. Heart Failure"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108861_bb0200","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): A multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"The Lancet. Diabetes & Endocrinology"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108861_bb0210","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108861_bb0215","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of Empagliflozin on heart failure outcomes after acute myocardial infarction: Insights from the EMPACT-MI Trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108861_bb0220","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc21-2043","article-title":"The SGLT2 inhibitor Dapagliflozin increases the oxidation of ingested fatty acids to ketones in type 2 diabetes","volume":"45","author":"Herring","year":"2022","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108861_bb0225","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/ejhf.2613","article-title":"Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation","volume":"24","author":"Higuchi","year":"2022","journal-title":"European Journal of Heart Failure"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0230","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacbts.2024.02.012","article-title":"Human Aortic stenotic Valve-derived extracellular vesicles induce endothelial dysfunction and Thrombogenicity through AT1R\/NADPH oxidases\/SGLT2 pro-oxidant pathway","volume":"9","author":"Hmadeh","year":"2024","journal-title":"JACC. Basic to Translational Science"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108861_bb0235","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1210\/en.2019-00422","article-title":"Hepatic Gluconeogenic response to single and Long-term SGLT2 inhibition in lean\/obese male hepatic G6pc-reporter mice","volume":"160","author":"Inaba","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.134929","article-title":"SGLT1 participates in the development of vascular cognitive impairment in a mouse model of small vessel disease","volume":"727","author":"Ishida","year":"2020","journal-title":"Neuroscience Letters"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108861_bb0245","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evidence"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108861_bb0250","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.3390\/molecules25163606","article-title":"Effects of Secretome from fat tissues on ion currents of cardiomyocyte modulated by sodium-glucose transporter 2 inhibitor","volume":"25","author":"Jhuo","year":"2020","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108861_bb0255","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"International Journal of Cancer"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108861_bb0260","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.124.069144","article-title":"Ertugliflozin for functional mitral regurgitation associated with heart failure: EFFORT Trial","volume":"149","author":"Kang","year":"2024","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108861_bb0265","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/01.RES.85.9.777","article-title":"The myocardial Na(+)-H(+) exchange: Structure, regulation, and its role in heart disease","volume":"85","author":"Karmazyn","year":"1999","journal-title":"Circulation Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0270","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s43587-024-00642-y","article-title":"SGLT2 inhibition eliminates senescent cells and alleviates pathological aging","volume":"4","author":"Katsuumi","year":"2024","journal-title":"Nature Aging"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108861_bb0275","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrcardio.2012.145","article-title":"Altered sarcoplasmic reticulum calcium cycling\u2014Targets for heart failure therapy","volume":"9","author":"Kho","year":"2012","journal-title":"Nature Reviews. Cardiology"},{"issue":"4S","key":"10.1016\/j.pharmthera.2025.108861_bb0280","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney International"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108861_bb0285","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108861_bb0290","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacep.2022.08.004","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation","volume":"8","author":"Kishima","year":"2022","journal-title":"JACC. Clinical Electrophysiology"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0295","doi-asserted-by":"crossref","first-page":"1005408","DOI":"10.3389\/fcvm.2023.1005408","article-title":"Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats","volume":"10","author":"Koizumi","year":"2023","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108861_bb0300","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and Anemia in patients with chronic kidney disease","volume":"2","author":"Koshino","year":"2023","journal-title":"NEJM Evidence"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108861_bb0305","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney International"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108861_bb0310","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/dom.15331","article-title":"Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis","volume":"26","author":"Kuate Defo","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108861_bb0315","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027824","article-title":"Sodium-glucose Cotransporter-2 inhibitors after acute myocardial infarction in patients with type 2 diabetes: A population-based investigation","volume":"12","author":"Kwon","year":"2023","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0320","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","article-title":"Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors","volume":"17","author":"Lahnwong","year":"2018","journal-title":"Cardiovascular Diabetology"},{"issue":"41","key":"10.1016\/j.pharmthera.2025.108861_bb0325","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: The EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"European Heart Journal"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0330","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.metabol.2009.10.025","article-title":"Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients","volume":"59","author":"von Lewinski","year":"2010","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0335","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0340","article-title":"Protective effects of sodium-glucose transporter 2 inhibitors on atrial fibrillation and atrial flutter: A systematic review and Meta- analysis of randomized placebo-controlled trials","volume":"12","author":"Li","year":"2021","journal-title":"Frontiers in Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0345","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: A systematic review with meta-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108861_bb0350","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.3390\/ijms22116044","article-title":"Sodium glucose co-transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species","volume":"22","author":"Li","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0355","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-024-02137-x","article-title":"Effect of SGLT-2 inhibitors on arrhythmia events: Insight from an updated secondary analysis of>80,000 patients (the SGLT2i-arrhythmias and sudden cardiac death)","volume":"23","author":"Liao","year":"2024","journal-title":"Cardiovascular Diabetology"},{"issue":"36","key":"10.1016\/j.pharmthera.2025.108861_bb0360","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1093\/eurheartj\/ehab563","article-title":"Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure","volume":"42","author":"Light","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0365","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovascular Diabetology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108861_bb0370","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC. Basic to Translational Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0380","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1038\/s41467-020-18165-6","article-title":"Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy","volume":"11","author":"Luczak","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0385","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/424751","article-title":"Oxidative stress in dilated cardiomyopathy caused by MYBPC3 mutation","volume":"2015","author":"Lynch","year":"2015","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"41","key":"10.1016\/j.pharmthera.2025.108861_bb0390","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"European Heart Journal"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108861_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100851","article-title":"SGLT2 inhibitor use in chronic kidney disease: Supporting cardiovascular, kidney, and metabolic health","volume":"6","author":"Madero","year":"2024","journal-title":"Kidney Medicine"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2025.108861_bb0400","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pbiomolbio.2007.07.010","article-title":"Late sodium current in failing heart: Friend or foe?","volume":"96","author":"Maltsev","year":"2008","journal-title":"Progress in Biophysics and Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0405","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106448","article-title":"Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes","volume":"184","author":"Marfella","year":"2022","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0415","doi-asserted-by":"crossref","unstructured":"Marx, N., Federici, M., Sch\u00fctt, K., M\u00fcller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., Espinola-Klein, C., Fauchier, L., Halle, M., Herrington, W. G., Kautzky-Willer, A., Lambrinou, E., Lesiak, M., Lettino, M., McGuire, D. K., \u2026 ESC Scientific Document Group. (2023). 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal, 44(39), 4043\u20134140. doi:https:\/\/doi.org\/10.1093\/eurheartj\/ehad192.","DOI":"10.1093\/eurheartj\/ehad192"},{"issue":"36","key":"10.1016\/j.pharmthera.2025.108861_bb0420","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0425","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","volume":"26","author":"McDonagh","year":"2024","journal-title":"European Journal of Heart Failure"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108861_bb0430","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and Reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"10367","key":"10.1016\/j.pharmthera.2025.108861_bb0435","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108861_bb0440","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2337\/dc21-2434","article-title":"Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with Preserved ejection fraction","volume":"45","author":"Mone","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121258","article-title":"Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: Role of BDNF, CREB and Npas4","volume":"312","author":"Mousa","year":"2023","journal-title":"Life Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108861_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232283","article-title":"Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)","volume":"15","author":"Nakano","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0455","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0460","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Nasiri-Ansari","year":"2018","journal-title":"Cardiovascular Diabetology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0465","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"19","key":"10.1016\/j.pharmthera.2025.108861_bb0470","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: A meta-analysis of individual participant data from randomized, Controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0475","doi-asserted-by":"crossref","first-page":"14872","DOI":"10.1038\/s41598-018-33293-2","article-title":"Empagliflozin Ammeliorates high glucose induced-cardiac Dysfuntion in human iPSC-derived cardiomyocytes","volume":"8","author":"Ng","year":"2018","journal-title":"Scientific Reports"},{"issue":"10365","key":"10.1016\/j.pharmthera.2025.108861_bb0480","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group & SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists'\u2019 Consortium","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108861_bb0485","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jce.15894","article-title":"SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta-analysis of randomized clinical trials","volume":"34","author":"Oates","year":"2023","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0490","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: An updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0495","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-023-01860-1","article-title":"Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: A systematic review","volume":"22","author":"Ouyang","year":"2023","journal-title":"Cardiovascular Diabetology"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108861_bb0500","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the Cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108861_bb0505","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108861_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0515","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12933-024-02504-8","article-title":"SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)","volume":"23","author":"Paolisso","year":"2024","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110766","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry","volume":"202","author":"Paolisso","year":"2023","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacological Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0530","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","article-title":"Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: A multicenter international registry","volume":"21","author":"Paolisso","year":"2022","journal-title":"Cardiovascular Diabetology"},{"issue":"23","key":"10.1016\/j.pharmthera.2025.108861_bb0535","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108861_bb0540","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ejhf.3184","article-title":"Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER","volume":"26","author":"Peikert","year":"2024","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0545","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3389\/fphys.2020.00912","article-title":"Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction","volume":"11","author":"Peng","year":"2020","journal-title":"Frontiers in Physiology"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108861_bb0550","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"45","key":"10.1016\/j.pharmthera.2025.108861_bb0555","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/eurheartj\/ehac417","article-title":"Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?","volume":"43","author":"Pitt","year":"2022","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0560","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1471-4159.1997.69010084.x","article-title":"Expression of the Na+-D-glucose cotransporter SGLT1 in neurons","volume":"69","author":"Poppe","year":"1997","journal-title":"Journal of Neurochemistry"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108861_bb0565","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108861_bb0570","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009521","article-title":"Defects in the proteome and metabolome in human hypertrophic cardiomyopathy","volume":"15","author":"Previs","year":"2022","journal-title":"Circulation. Heart Failure"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108861_bb0821","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation","volume":"392","author":"Raposeiras-Roubin","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108861_bb0575","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1111\/dom.13468","article-title":"Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?","volume":"20","author":"Raschi","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108861_bb0580","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1681\/ASN.2022050623","article-title":"Treatment effect of the SGLT2 inhibitor Empagliflozin on chronic syndrome of inappropriate Antidiuresis: Results of a randomized, double-blind, placebo-controlled, crossover Trial","volume":"34","author":"Refardt","year":"2023","journal-title":"Journal of the American Society of Nephrology: JASN"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0585","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/s41401-021-00805-2","article-title":"Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress","volume":"43","author":"Ren","year":"2022","journal-title":"Acta Pharmacologica Sinica"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43441-020-00211-6","article-title":"FDA\u2019S new guidance for industry addressing evaluation of the safety of new drugs for improving glycemic control: A case study in regulatory science","volume":"55","author":"Rick Turner","year":"2021","journal-title":"Therapeutic Innovation & Regulatory Science"},{"issue":"27","key":"10.1016\/j.pharmthera.2025.108861_bb0595","doi-asserted-by":"crossref","first-page":"10487","DOI":"10.1074\/jbc.RA118.002081","article-title":"Hypertrophic cardiomyopathy mutations increase myofilament Ca2+ buffering, alter intracellular Ca2+ handling, and stimulate Ca2+\u2212dependent signaling","volume":"293","author":"Robinson","year":"2018","journal-title":"The Journal of Biological Chemistry"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108861_bb0600","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0605","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777083","article-title":"Effects of sodium-glucose transporter 2 inhibitors (SGLT2-I) in patients with ischemic heart disease (IHD) treated by coronary artery bypass grafting via MiECC: Inflammatory burden, and clinical outcomes at 5 years of follow-up","volume":"12","author":"Sardu","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12997\/jla.2022.11.1.1","article-title":"SGLT2 inhibitors and ketone metabolism in heart failure","volume":"11","author":"Saucedo-Orozco","year":"2022","journal-title":"Journal of Lipid and Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0615","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12933-020-01141-1","article-title":"Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure","volume":"19","author":"Sayour","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0620","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0625","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clinical Pharmacokinetics"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108861_bb0630","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.3145","article-title":"Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study","volume":"26","author":"Scisciola","year":"2024","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0635","first-page":"20","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: A meta-analysis of randomized controlled trials","volume":"24","author":"Sfairopoulos","year":"2022","journal-title":"Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology: Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0640","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12964-023-01077-5","article-title":"Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy","volume":"21","author":"Shi","year":"2023","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0645","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: The EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0650","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: Population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108861_bb0655","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/liv.15851","article-title":"Sodium-glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use","volume":"44","author":"Siafarikas","year":"2024","journal-title":"Liver International: Official Journal of the International Association for the Study of the Liver"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.708547","article-title":"Role of DPP-4 and SGLT2 inhibitors connected to Alzheimer disease in type 2 diabetes mellitus","volume":"15","author":"Sim","year":"2021","journal-title":"Frontiers in Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108861_bb0665","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly Reduced or Preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0670","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/jcdd10070287","article-title":"Metabolic approaches for the treatment of dilated cardiomyopathy","volume":"10","author":"Spoladore","year":"2023","journal-title":"Journal of Cardiovascular Development and Disease"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108861_bb0675","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108861_bb0680","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.3390\/ijms22157976","article-title":"Cardioprotection by SGLT2 inhibitors-does it all come down to Na+?","volume":"22","author":"Trum","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108861_bb0685","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ejhf.3129","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis","volume":"26","author":"Usman","year":"2024","journal-title":"European Journal of Heart Failure"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108861_bb0690","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3892\/etm.2023.11824","article-title":"Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second-generation antipsychotics (review)","volume":"25","author":"Vasiliu","year":"2023","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108861_bb0695","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11897-017-0340-1","article-title":"Role of SGLT2 inhibitors in patients with diabetes mellitus and heart failure","volume":"14","author":"Verbrugge","year":"2017","journal-title":"Current Heart Failure Reports"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108861_bb0700","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of Empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART CardioLink-6 randomized clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0705","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/eurjpc\/zwad372","article-title":"SGLT2 inhibitors: A therapy for everybody but not for anything?","volume":"31","author":"Villaschi","year":"2024","journal-title":"European Journal of Preventive Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108861_bb0710","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108861_bb0715","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/dom.13620","article-title":"The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis","volume":"21","author":"Wang","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108861_bb0720","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00198-023-06908-2","article-title":"Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"34","author":"Wang","year":"2023","journal-title":"Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108861_bb0725","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: A nested case-control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"European Journal of Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108861_bb0730","doi-asserted-by":"crossref","DOI":"10.1128\/mcb.00282-21","article-title":"Inhibition of SGLT1 alleviates the glycemic variability-induced cardiac fibrosis via inhibition of activation of macrophage and cardiac fibroblasts","volume":"42","author":"Wu","year":"2022","journal-title":"Molecular and Cellular Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108861_bb0735","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s00392-024-02386-6","article-title":"Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"113","author":"Xu","year":"2024","journal-title":"Clinical Research in Cardiology: Official Journal of the German Cardiac Society"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0740","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: Expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney International Reports"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108861_bb0745","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin attenuates Na+\/H+ exchanger-1 in cardiofibroblasts via AMPK activation","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108861_bb0750","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/CIRCULATIONAHA.122.063327","article-title":"Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: Findings from DAPA-HF","volume":"147","author":"Yeoh","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2025.108861_bb0755","article-title":"Extrarenal benefits of SGLT2 inhibitors in the treatment of cardiomyopathy","author":"Yerra","year":"2024","journal-title":"Physiology (Bethesda, Md.)"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0760","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.3390\/ijms24076039","article-title":"Unlocking the full potential of SGLT2 inhibitors: Expanding applications beyond glycemic control","volume":"24","author":"Youssef","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0765","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12888-024-05627-0","article-title":"Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: A randomized double-blind, placebo-controlled clinical trial","volume":"24","author":"Zandifar","year":"2024","journal-title":"BMC Psychiatry"},{"issue":"10254","key":"10.1016\/j.pharmthera.2025.108861_bb0770","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet (London, England)"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108861_bb0775","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of Dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: Insights from the DECLARE-TIMI 58 Trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108861_bb0780","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/eurjpc\/zwad356","article-title":"Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: A systemic review and meta-analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"European Journal of Preventive Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108861_bb0785","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovascular Diabetology"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108861_bb0790","doi-asserted-by":"crossref","first-page":"H1385","DOI":"10.1152\/ajpheart.01167.2011","article-title":"Cross talk between cardiac myocytes and fibroblasts: From multiscale investigative approaches to mechanisms and functional consequences","volume":"303","author":"Zhang","year":"2012","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"issue":"39","key":"10.1016\/j.pharmthera.2025.108861_bb0795","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027362","article-title":"Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: A meta-analysis of cardiovascular outcome trials","volume":"100","author":"Zhao","year":"2021","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108861_bb0800","first-page":"1251","article-title":"Effect of Dapagliflozin combined with cognitive behavior training on quality of life and cognitive function in elderly patients with type 2 diabetes mellitus complicated with mild cognitive impairment","volume":"51","author":"Zhao","year":"2022","journal-title":"Iranian Journal of Public Health"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108861_bb0805","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031269","article-title":"Impact of sodium-glucose cotransporter 2 inhibitor on recurrence after catheter ablation for atrial fibrillation in patients with diabetes: A propensity-score matching study and Meta-analysis","volume":"12","author":"Zhao","year":"2023","journal-title":"Journal of the American Heart Association"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108861_bb0810","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","article-title":"Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE Trial and meta-analysis","volume":"52","author":"Zhou","year":"2021","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108861_bb0815","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of glucose-lowering medications with cardiovascular outcomes: An umbrella review and evidence map","volume":"8","author":"Zhu","year":"2020","journal-title":"The Lancet. Diabetes & Endocrinology"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108861_bb0820","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"The New England Journal of Medicine"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T13:47:01Z","timestamp":1753796821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":163,"alternative-id":["S0163725825000737"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108861","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108861"}}